Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew L Frelinger

Showing results (61-70 of 95) with videos related to

Pageof 10
Sort By:
Blood|February 2, 2012
In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activationBethan Psaila, James B Bussel, Matthew D Linden, et al.
Journal of Thrombosis and Haemostasis : JTH|September 28, 2021
Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet PhysiologyAndrew L Frelinger, José Rivera, David E Connor, et al.
Thrombosis Research|December 26, 2013
A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulationJoseph A Jakubowski, Chunmei Zhou, Stipo Jurcevic, et al.
Journal of the American College of Cardiology|September 18, 2010
Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) studyDominick J Angiolillo, Jorge F Saucedo, Roger Deraad, et al.
Blood|February 12, 2005
Platelet activation in cystic fibrosisBrian P O'Sullivan, Matthew D Linden, Andrew L Frelinger, et al.
European Journal of Medicinal Chemistry|November 21, 2015
New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptorsIvan B Yanachkov, Hung Chang, Milka I Yanachkova, et al.
British Journal of Clinical Pharmacology|November 23, 2012
A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivityJoseph A Jakubowski, Chunmei Zhou, David S Small, et al.
Plos One|September 21, 2011
The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviorsFrank A J L Scheer, Alan D Michelson, Andrew L Frelinger, et al.
Thrombosis and Haemostasis|March 25, 2016
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 TrialEdward T Carreras, Willibald Hochholzer, Andrew L Frelinger, et al.
Acta Haematologica|June 12, 2013
Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot studyHung Chang, Lee-Yung Shih, Alan D Michelson, et al.
Pageof 10

Showing results (61-70 of 95) with videos related to

Sort By:
Pageof 10
Blood|February 2, 2012
In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activationBethan Psaila, James B Bussel, Matthew D Linden, et al.
Journal of Thrombosis and Haemostasis : JTH|September 28, 2021
Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet PhysiologyAndrew L Frelinger, José Rivera, David E Connor, et al.
Thrombosis Research|December 26, 2013
A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulationJoseph A Jakubowski, Chunmei Zhou, Stipo Jurcevic, et al.
Journal of the American College of Cardiology|September 18, 2010
Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) studyDominick J Angiolillo, Jorge F Saucedo, Roger Deraad, et al.
Blood|February 12, 2005
Platelet activation in cystic fibrosisBrian P O'Sullivan, Matthew D Linden, Andrew L Frelinger, et al.
European Journal of Medicinal Chemistry|November 21, 2015
New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptorsIvan B Yanachkov, Hung Chang, Milka I Yanachkova, et al.
British Journal of Clinical Pharmacology|November 23, 2012
A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivityJoseph A Jakubowski, Chunmei Zhou, David S Small, et al.
Plos One|September 21, 2011
The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviorsFrank A J L Scheer, Alan D Michelson, Andrew L Frelinger, et al.
Thrombosis and Haemostasis|March 25, 2016
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 TrialEdward T Carreras, Willibald Hochholzer, Andrew L Frelinger, et al.
Acta Haematologica|June 12, 2013
Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot studyHung Chang, Lee-Yung Shih, Alan D Michelson, et al.
Pageof 10